MX2024003510A - Metodos para tratar trastornos de perdida del cabello con inhibidores de la tirosina cinasa 2 (tyk2). - Google Patents
Metodos para tratar trastornos de perdida del cabello con inhibidores de la tirosina cinasa 2 (tyk2).Info
- Publication number
- MX2024003510A MX2024003510A MX2024003510A MX2024003510A MX2024003510A MX 2024003510 A MX2024003510 A MX 2024003510A MX 2024003510 A MX2024003510 A MX 2024003510A MX 2024003510 A MX2024003510 A MX 2024003510A MX 2024003510 A MX2024003510 A MX 2024003510A
- Authority
- MX
- Mexico
- Prior art keywords
- tyk2
- methods
- hair loss
- inhibitors
- tyrosine kinase
- Prior art date
Links
- 201000004384 Alopecia Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 208000024963 hair loss Diseases 0.000 title abstract 2
- 230000003676 hair loss Effects 0.000 title abstract 2
- 102000015774 TYK2 Kinase Human genes 0.000 title 2
- 108010010057 TYK2 Kinase Proteins 0.000 title 2
- 239000003112 inhibitor Substances 0.000 title 1
- 229940123371 Tyrosine kinase 2 inhibitor Drugs 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000004631 alopecia areata Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163247672P | 2021-09-23 | 2021-09-23 | |
| PCT/US2022/044346 WO2023049241A1 (en) | 2021-09-23 | 2022-09-22 | Methods of treating hair-loss disorders with tyk2 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024003510A true MX2024003510A (es) | 2024-04-09 |
Family
ID=83899658
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024003510A MX2024003510A (es) | 2021-09-23 | 2022-09-22 | Metodos para tratar trastornos de perdida del cabello con inhibidores de la tirosina cinasa 2 (tyk2). |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240390372A1 (https=) |
| EP (1) | EP4404930A1 (https=) |
| JP (1) | JP2024533700A (https=) |
| KR (1) | KR20240065283A (https=) |
| CN (2) | CN118251222A (https=) |
| AU (1) | AU2022350509A1 (https=) |
| CA (1) | CA3232812A1 (https=) |
| IL (1) | IL311624A (https=) |
| MX (1) | MX2024003510A (https=) |
| WO (1) | WO2023049241A1 (https=) |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3495358T (lt) | 2012-11-08 | 2022-05-25 | Bristol-Myers Squibb Company | Amidais pakeisti heterocikliniai junginiai, naudingi kaip il-12, il-23 ir (arba) ifn alfa atsako moduliatoriai |
| TWI582077B (zh) * | 2013-11-07 | 2017-05-11 | 必治妥美雅史谷比公司 | 作爲ＩＬ－１２、ＩＬ－２３及／或ＩＦＮα反應調節劑之經烷基－醯胺取代之吡啶化合物 |
| TW202515876A (zh) * | 2017-03-08 | 2025-04-16 | 日商武田藥品工業股份有限公司 | Tyk2抑制劑及其用途 |
| JP7113023B2 (ja) * | 2017-03-30 | 2022-08-04 | ブリストル－マイヤーズ スクイブ カンパニー | ６－（シクロプロパンアミド）－４－（（２－メトキシ－３－（１－メチル－１ｈ－１，２，４－トリアゾール－３－イル）フェニル）アミノ）－ｎ－（メチル－ｄ３）ピリダジン－３－カルボキシアミドの製造方法 |
| KR102848769B1 (ko) | 2018-05-31 | 2025-08-20 | 브리스톨-마이어스 스큅 컴퍼니 | 6-(시클로프로판카르복스아미도)-4-((2-메톡시-3-(1-메틸-1h-1,2,4-트리아졸-3-일)페닐)아미노)-n-(메틸-d3) 피리다진-3-카르복스아미드의 결정질 형태 |
| US20230093099A1 (en) * | 2019-04-02 | 2023-03-23 | Cullgen (Shanghai), Inc. | Compounds and methods of treating cancers |
| US11357775B2 (en) * | 2019-04-30 | 2022-06-14 | Celgene Corporation | Combination therapies comprising apremilast and Tyk2 inhibitors |
| SG11202112043PA (en) * | 2019-04-30 | 2021-11-29 | Celgene Corp | Combination therapies comprising apremilast and tyk2 inhibitors |
| US12570637B2 (en) | 2019-06-12 | 2026-03-10 | Bristol-Myers Squibb Company | Crystalline salt forms 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyld3) pyridazine-3-carboxamide |
| JP7812785B2 (ja) | 2019-09-18 | 2026-02-10 | ブリストル－マイヤーズ スクイブ カンパニー | Ｔｙｋ２阻害薬の剤形 |
| AU2021205465A1 (en) * | 2020-01-06 | 2022-07-14 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the S1P1 receptor |
| CN111704617B (zh) * | 2020-06-15 | 2022-08-23 | 嘉兴特科罗生物科技有限公司 | 一种小分子化合物 |
| CN112142675B (zh) * | 2020-10-09 | 2021-11-30 | 嘉兴特科罗生物科技有限公司 | 一种作为jak激酶抑制剂的小分子化合物及其用途 |
-
2022
- 2022-09-22 EP EP22792963.5A patent/EP4404930A1/en active Pending
- 2022-09-22 JP JP2024518606A patent/JP2024533700A/ja active Pending
- 2022-09-22 CN CN202280075809.3A patent/CN118251222A/zh active Pending
- 2022-09-22 KR KR1020247012854A patent/KR20240065283A/ko active Pending
- 2022-09-22 AU AU2022350509A patent/AU2022350509A1/en active Pending
- 2022-09-22 CN CN202411332236.5A patent/CN119345364A/zh active Pending
- 2022-09-22 CA CA3232812A patent/CA3232812A1/en active Pending
- 2022-09-22 MX MX2024003510A patent/MX2024003510A/es unknown
- 2022-09-22 US US18/694,424 patent/US20240390372A1/en active Pending
- 2022-09-22 WO PCT/US2022/044346 patent/WO2023049241A1/en not_active Ceased
- 2022-09-22 IL IL311624A patent/IL311624A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240065283A (ko) | 2024-05-14 |
| CA3232812A1 (en) | 2023-03-30 |
| JP2024533700A (ja) | 2024-09-12 |
| IL311624A (en) | 2024-05-01 |
| EP4404930A1 (en) | 2024-07-31 |
| US20240390372A1 (en) | 2024-11-28 |
| AU2022350509A1 (en) | 2024-04-04 |
| WO2023049241A1 (en) | 2023-03-30 |
| CN118251222A (zh) | 2024-06-25 |
| CN119345364A (zh) | 2025-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP24009853A (es) | Compuestos tricíclicos como inhibidores de kras | |
| CL2020002146A1 (es) | Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer. | |
| CL2020001133A1 (es) | Compuestos heterocíclicos sustituidos con amina como inhibidores de ehmt2 y métodos de uso de los mismos. (divisional solicitud 201901664) | |
| CO2021011188A2 (es) | Compuesto heterocíclico y su uso | |
| CO2021009078A2 (es) | Pirazolopirimidinas sustituidas y purinas sustituidas y su uso como inhibidores de proteasa procesadora específica de ubiquitina 1 (usp1) | |
| CO2025015814A2 (es) | Inhibidores de kras de 2-azabiciclo [2.2.1] heptano | |
| CO2021009882A2 (es) | Inhibidores aza-heterobicíclicos de mat2a y métodos de uso en el tratamiento de cáncer | |
| MX389700B (es) | Derivados de pirazolopiridina como moduladores de cinasa 1 progenitora hematopoyetica (hpk1) y usos de los mismos para tratamiento de cancer. | |
| CO2021001219A2 (es) | Benzimidazoles sustituidos como inhibidores de pad4 | |
| MX2023002325A (es) | Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados. | |
| CO2022000266A2 (es) | Inhibidores de enzimas | |
| CO2025005378A2 (es) | Compuestos n-(5-sustituido-[(1,3,4-tiadiazolil) o (1,3-tiazolil)](sustituido)carboxamida, composiciones farmacéuticas y métodos de preparación de los compuestos amida y de su uso | |
| CL2022001368A1 (es) | Uso de inhibidores de sglt-2 en el secado de mamíferos no humanos | |
| MX2023002579A (es) | Triptaminas de azetidinil y metodos para el tratamiento de trastornos psiquiatricos. | |
| CO2023018652A2 (es) | Compuestos de triptamina fluorada, análogos de estos y métodos de uso de estos | |
| CO2023012342A2 (es) | Inhibidores de enzimas | |
| CO2022008690A2 (es) | Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso | |
| ECSP21003171A (es) | Dinucleótidos cíclicos como agonistas de sting | |
| JOP20230090A1 (ar) | نظم لعلاج الاضطرابات المتعلقة بفقدان الشعر باستخدام مثبطات jak معالجة بالديوتريوم | |
| CL2025002636A1 (es) | Uso inhibidor de pde10 para tratamiento del síndrome de tourette (divisional de solicitud no. 202203400) | |
| CO2020007129A2 (es) | Tratamientos de combinación que comprenden la administración de 1h-pirazolo[4,3-b]piridinas | |
| CR11860A (es) | Derivados de dibenzotiazepina y sus usos - 424 | |
| MX2024003510A (es) | Metodos para tratar trastornos de perdida del cabello con inhibidores de la tirosina cinasa 2 (tyk2). | |
| AR131202A1 (es) | Compuesto heterocíclico y uso del mismo | |
| UY38972A (es) | Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso |